1. Home
  2. VIR vs CNNE Comparison

VIR vs CNNE Comparison

Compare VIR & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.37

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

CNNE

Cannae Holdings Inc.

HOLD

Current Price

$11.07

Market Cap

608.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIR
CNNE
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
608.0M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
VIR
CNNE
Price
$9.37
$11.07
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
$19.63
$21.33
AVG Volume (30 Days)
4.4M
636.4K
Earning Date
05-06-2026
02-23-2026
Dividend Yield
N/A
5.28%
EPS Growth
17.49
N/A
EPS
N/A
N/A
Revenue
$68,556,000.00
$499,700,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,049.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.37
52 Week Low
$4.16
$11.30
52 Week High
$10.91
$21.96

Technical Indicators

Market Signals
Indicator
VIR
CNNE
Relative Strength Index (RSI) 56.02 31.82
Support Level $8.67 N/A
Resistance Level $10.29 $16.41
Average True Range (ATR) 0.58 0.40
MACD -0.09 0.04
Stochastic Oscillator 42.28 17.02

Price Performance

Historical Comparison
VIR
CNNE

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

About CNNE Cannae Holdings Inc.

Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.

Share on Social Networks: